文献速递乳腺MR

基于MRI瘤内异质性量化的列线图预测乳腺癌新辅助化疗反应

Nomogram for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer Using MRI-based Intratumoral Heterogeneity Quantification.
PubMed 文献 · Radiology · 2025-01-01

这项回顾性研究纳入九个中心1988年4月至2023年12月接受新辅助化疗的乳腺癌患者,利用治疗前MRI量化瘤内异质性并构建列线图预测病理完全缓解和无复发生存,瘤内异质性评分是病理完全缓解的独立预测因子,列线图在三个外部验证集中AUC分别为0.82、0.81和0.79。

要点

  • 瘤内异质性评分是病理完全缓解的独立预测因子(比值比0.12,P<.001)。
  • 列线图在三个外部验证集的AUC分别为0.82、0.81和0.79。
  • 列线图评分较低与无复发生存较差相关(风险比4.04,P<.001)。

核心结论

  • 联合瘤内异质性评分与临床病理变量的列线图模型在预测新辅助化疗病理完全缓解和无复发生存方面表现良好。

研究设计与样本

  • 回顾性研究,纳入1988年4月至2023年12月在九个中心接受新辅助化疗的乳腺癌患者1448例(中位年龄49岁,IQR 43-54岁)。
  • 以中心A的505例患者为训练集,中心B、中心C-F、中心G的患者分别为三个外部验证集(n分别为331、107、384)。
  • 生存数据集包括中心A和H的患者(n=179),基因组学数据集包括中心I的患者(n=74)。

诊断标准与关键数值

  • 瘤内异质性评分是病理完全缓解的独立预测因子(比值比0.12,95%CI 0.03-0.43,P<.001)。
  • 列线图模型在三个外部验证集的受试者工作特征曲线下面积分别为0.82、0.81和0.79。
  • 列线图评分较低与无复发生存较差相关(风险比4.04,95%CI 1.90-8.60,P<.001)。
  • 列线图评分较低与肿瘤增殖相关生物学通路的上调相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Intratumoral heterogeneity (ITH) in breast cancer contributes to treatment failure and relapse. Noninvasive methods to quantify ITH are currently limited. Purpose To quantify ITH in breast cancer using pretreatment MRI, develop a nomogram to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and recurrence-free survival (RFS), and investigate biologic pathways associated with nomogram scores. Materials and Methods This retrospective study included patients with breast cancer who underwent NAC at nine centers between April 1988 and December 2023. Tumor regions on MRI scans were clustered and integrated with global pixel distribution patterns to calculate ITH scores. A nomogram for predicting pCR was developed using multivariable logistic regression. A survival dataset was used to evaluate the association between nomogram score and RFS, and a genomics dataset was used to explore the relationship between nomogram score and biologic pathways. Results The study included 1448 women (median age, 49 years [IQR, 43-54 years]). To predict pCR to NAC, the 505 patients from center A served as the training set, and the patients from center B, centers C-F, and center G served as three external validation sets (n = 331, 107, and 384, respectively). The survival set included patients from centers A and H (n = 179), and the genomics set included patients from center I (n = 74). The ITH score was an independent predictor of pCR (odds ratio, 0.12 [95% CI: 0.03, 0.43]; P < .001). The nomogram model achieved area under the receiver operating characteristic curve values of 0.82, 0.81, and 0.79, respectively, in the three external validation sets. A lower nomogram score was correlated with poorer RFS (hazard ratio, 4.04 [95% CI: 1.90, 8.60]; P < .001) and was associated with upregulation of biologic pathways related to tumor proliferation. Conclusion A nomogram model combining ITH score and clinicopathologic variables showed good performance in predicting pCR to NAC and RFS. Published under a CC BY 4.0 license. Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Huang Y, Wang X, Cao Y, et al. Nomogram for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer Using MRI-based Intratumoral Heterogeneity Quantification. Radiology. 2025. PMID: 40232145. doi:10.1148/radiol.241805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。